[{"address1": "1715 38th Street", "city": "Boulder", "state": "CO", "zip": "80301", "country": "United States", "phone": "720 262 7002", "website": "https://www.edgewisetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.", "fullTimeEmployees": 97, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter A. Thompson FACP, M.D.", "age": 63, "title": "Co-Founder & Independent Chairman", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 76000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Koch Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 905520, "exercisedValue": 0, "unexercisedValue": 15434982}, {"maxAge": 1, "name": "Dr. Badreddin  Edris Ph.D.", "age": 36, "title": "Co-Founder & Independent Director", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 43000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Behrad  Derakhshan Ph.D.", "age": 43, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 630667, "exercisedValue": 0, "unexercisedValue": 3550001}, {"maxAge": 1, "name": "Dr. Joanne M. Donovan M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 696400, "exercisedValue": 0, "unexercisedValue": 108331}, {"maxAge": 1, "name": "Dr. Alan J. Russell Ph.D.", "age": 53, "title": "Co-Founder, Chief Scientific Officer & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 657520, "exercisedValue": 0, "unexercisedValue": 18564558}, {"maxAge": 1, "name": "Mr. R. Michael Carruthers", "age": 65, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 386009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John R. Moore", "age": 59, "title": "General Counsel", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Semigran M.D.", "age": 66, "title": "Chief Development Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 27.31, "open": 27.3, "dayLow": 26.54, "dayHigh": 27.87, "regularMarketPreviousClose": 27.31, "regularMarketOpen": 27.3, "regularMarketDayLow": 26.54, "regularMarketDayHigh": 27.87, "beta": 0.158, "forwardPE": -14.57754, "volume": 1113208, "regularMarketVolume": 1113208, "averageVolume": 1157269, "averageVolume10days": 2522010, "averageDailyVolume10Day": 2522010, "bid": 27.24, "ask": 27.35, "bidSize": 100, "askSize": 300, "marketCap": 2559984128, "fiftyTwoWeekLow": 5.12, "fiftyTwoWeekHigh": 30.0, "fiftyDayAverage": 19.7939, "twoHundredDayAverage": 17.457726, "currency": "USD", "enterpriseValue": 2049466624, "floatShares": 53520533, "sharesOutstanding": 93772304, "sharesShort": 8169156, "sharesShortPriorMonth": 6396177, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0871, "heldPercentInsiders": 0.0046900003, "heldPercentInstitutions": 1.11711, "shortRatio": 10.34, "shortPercentOfFloat": 0.128, "impliedSharesOutstanding": 93909904, "bookValue": 5.451, "priceToBook": 5.000917, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -115878000, "trailingEps": -1.53, "forwardEps": -1.87, "enterpriseToEbitda": -15.262, "52WeekChange": 3.0325446, "SandP52WeekChange": 0.34083736, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "EWTX", "underlyingSymbol": "EWTX", "shortName": "Edgewise Therapeutics, Inc.", "longName": "Edgewise Therapeutics, Inc.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "77e29508-1f39-3f61-9983-58dcf3724587", "messageBoardId": "finmb_595539666", "gmtOffSetMilliseconds": -14400000, "currentPrice": 27.26, "targetHighPrice": 48.0, "targetLowPrice": 33.0, "targetMeanPrice": 41.8, "targetMedianPrice": 42.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 511751008, "totalCashPerShare": 5.457, "ebitda": -134288992, "totalDebt": 4985000, "quickRatio": 29.795, "currentRatio": 30.242, "debtToEquity": 0.977, "returnOnAssets": -0.19740999, "returnOnEquity": -0.28197, "freeCashflow": -62309752, "operatingCashflow": -103585000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]